HIGHLIGHTS
- who: Zamagni E. et al. from the Dipartimento Area Medica, Università Udine, Udine, Italy have published the paper: The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma, in the Journal: (JOURNAL)
- what: The study is still on-going; a first analysis after enrollment of the first 29 patients showed that the rate of MRD negativity was 83%, with no differences between the two schedules of administration .
- future: Studies are needed to identify the best treatment strategy for HR patients. The ability of MoAbs to induce higher rates of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.